This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Dinona Inc., Kumho Ht, Inc.. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Soseul Kim: Innovator in Antibody Development
Introduction
Soseul Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunology, particularly in the development of antibodies for treating diseases related to myeloid-derived suppressor cells (MDSCs). With a total of 2 patents, his work is paving the way for innovative therapeutic approaches.
Latest Patents
Soseul Kim's latest patents focus on the use of antibodies that specifically bind to CD66c, a marker expressed in MDSCs. The first patent describes an antibody or an antigen-binding fragment that can be utilized for preventing and treating diseases associated with MDSCs. This invention highlights the potential of targeting MDSCs to alleviate immunosuppression in various diseases. The second patent details an anti-CD66c antibody that can induce T-cell activation or humoral immune response, offering a promising avenue for cancer treatment. This patent also includes a nucleic acid molecule encoding the antibody, a vector, and a host cell for the diagnosis and treatment of CD66c-related diseases.
Career Highlights
Throughout his career, Soseul Kim has worked with notable companies such as Dinona Inc. and Kumho HT, Inc. His experience in these organizations has contributed to his expertise in antibody development and immunotherapy.
Collaborations
Soseul Kim has collaborated with esteemed colleagues, including Sangsoon Yoon and Gil Yong Ji. These partnerships have further enhanced his research and innovation in the field.
Conclusion
Soseul Kim's work in developing antibodies targeting CD66c represents a significant advancement in the treatment of diseases related to myeloid-derived suppressor cells. His contributions are expected to have a lasting impact on immunotherapy and cancer treatment.